● Recruiting

GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）

Condition: Advanced Biliary Tract Cancer · Sponsor: Fudan University

PhaseN/A

Planned participants100

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

To evaluate the efficacy and immune microenvironment changes in treatment-naïve advanced biliary tract cancer (BTC) patients receiving first-line standard therapy with gemcitabine/cisplatin (GemCis) combined with PD-1/PD-L1 inhibitors.

This description comes directly from the study's public registry record.

Talk to the study team

Peng Wang, MD · 86-21-64041990 · peng_wang@fudan.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06988592